Q2 2019 Earnings

Revenue

$102M+26.0% YoY

Gross Profit

$91M88.9% margin

Operating Income

$22M21.1% margin

Net Income

$12M12.0% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

+48.7%

Operating Cash Flow

-$9M

Free Cash Flow

-$7M

Stock-Based Comp.

$5M

Total Assets

$316M

Total Liabilities

$535M

Stockholders' Equity

-$219M

Cash & Equivalents

$99M

Metric	Current	Year Ago	Change
Revenue	$102M	$81M	+26.0%
Gross Profit	$91M	$77M	+18.0%
Operating Income	$22M	-$40M	+154.1%
Net Income	$12M	-$49M	+124.9%

Collaborative Arrangements

$77M74%

Active Pharmaceutical Ingredient

$25M24%

Collaborative Arrangement Co Promotion Agreement

$1M1%

Collaborative Arrangement Co Promotion And Other Agreements

$500,0000%

Collaborative Arrangement Other Agreements

$323,0000%

$25M99%

Europe And Other

$262,0001%